Notícias e Atividades da Neurocrine Biosciences

Neurocrine Biosciences é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Neurocrine Biosciences é uma empresa listada sob o símbolo NBIX (US).

Fusão, aquisição e financiamento envolvendo Neurocrine Biosciences.

• Neurocrine Biosciences adquiriu Soleno Therapeutics (publicado em 18 de maio de 2026).
• Neurocrine Biosciences has announced the acquisition of Soleno Therapeutics  (publicado em 7 de abril de 2026).

Veja o organograma con seus 58 executivos principais

Biografias mais buscadas da Neurocrine Biosciences

• Kyle Gano, Chief Executive Officer
• Shalini Sharp, Director
• Stephen Sherwin, Director

Recentes movimentos de executivos em Neurocrine Biosciences

• Andrew Ratz antes Senior Vice President, Drug Development, Delivery and Device, foi promovido a Chief Technical Operations Officer  (Notícia publicada em 18 de março de 2026).
• Mike Sibley, ingressou na Companhia como Senior Vice President and General Manager, Neuropsychiatry Franchise  (Notícia publicada em 7 de outubro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Neurocrine Biosciences.

Neurocrine Biosciences possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (publicado em 4 de junho de 2026).
• Oak Hill Bio acaba de anunciar uma arrecadação de fundos de 33 milhões de dólares. (publicado em 4 de junho de 2026).
• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Patrick Enright - Director da CuraSen Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Neurocrine Biosciences

• Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder | Neurocrine Biosciences
• Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden | Neurocrine Biosciences
• Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025 | Neurocrine Biosciences
• News & Media —
• Neurocrine Biosciences to Present at Upcoming Investor Conferences in September | Neurocrine Biosciences
• Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference | Neurocrine Biosciences
• Neurocrine Biosciences Reports Second Quarter 2025 Financial Results | Neurocrine Biosciences
• Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025 | Neurocrine Biosciences
• Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025 | Neurocrine Biosciences
• Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting | Neurocrine Biosciences
• View more press releases Close

Redes sociais sobre Neurocrine Biosciences

• Neurocrine Biosciences na Wikipedia, Google News e Yahoo Finance
• Neurocrine Biosciences na LinkedIn, X (Twitter) e YouTube